June 20, 2006
VANCOUVER, Canada- iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at EPIC, a European Partnering and Investment Conference taking place June 22nd at the Cumberland Hotel in London, England.
EPIC is a biotechnology conference which showcases over 60 UK and European biotechnology companies. EPIC presents growing biotechnology companies an excellent opportunity to speak to an audience of potential partners, investors and professional advisors that could help to further develop their companies.
“EPIC is an excellent forum to promote the Company’s progress with iCo-007, the first product in our ocular franchise, as well as explore new financing opportunities. We are pleased to have been invited to present before such an influential community,” stated Mr. Rae.
Mr. Rae’s presentation will take place on Thursday, June 22nd at 2:00 pm. For more information on EPIC, visit the conference website at http://www.epicbiotech.com.
About iCo Therapeutics, Inc.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: https://icotherapeutics.com.
Business Development Contact:
Dr. John Clement, CTO
Mr. John Meekison, CFO